FOXO1 and acute lymphoblastic leukemia: The first B cell‐related study of FoxO1 inhibition was performed in B cell precursor acute lymphoblastic leukemia (BCP‐ALL), where the fine‐tuned FoxO1 activity allows for low‐level DNA damage susceptibility and clonal ALL cell evolution (Fig. 5) [113, 114, 115, 116].